


www.forum-onkologie.eu



EUROPEAN FORUM ON ONCOLOGY 2012

Advances in Cancer Therapy

3rd and 4th May 2012

Hotel Concorde BERLIN

P R O G R A M M E

COORDINATION

Gesundheitsstadt Berlin GmbH
www.gesundheitsstadt-berlin.de

ORGANIZER

WISO S. E. Consulting GmbH
www.wiso-gruppe.de

SCIENTIFIC PARTNERS



Thursday 3rd May 2012

08.30 - 10.00	Handing Out of Conference Documents		
10.00 - 11.30	OPENING		
11.30 - 13.00	PANEL DISCUSSION		
	Which Are The Primary Tasks and Responsibilities in European Oncology?		
13.00 - 13.45	Lunch Break		
13.45 - 15.15	SYMPOSIUM		
	Central Structural Issues in Europe		
15.15 - 15.45	Coffee Break		
15.45 - 17.15	WORKSHOP 1	WORKSHOP 2	WORKSHOP 3
	A National Initiative of Translational Cancer Research – the German Consortium of Translational Cancer Research	What Are the Determining Factors for Successful Translation?	What Differences in Outcomes Exist and How Can the Best Treatments be Standardized Throughout Europe?
17.15 - 17.30	Break		
17.30 - 18.45	PANEL DISCUSSION		
	What Needs to Be Improved in Currently Existing Structures for Research and Healthcare?		
18.45 - 19.15	GET-TOGETHER		

 Friday 4th May 2012

08.30 - 09.00	Handing Out of Conference Documents		
09.00 - 10.30	WORKSHOP 4	WORKSHOP 5	WORKSHOP 6
	Which Prevention and Treatment Approaches Promise Success?	Organizational Concepts for Comprehensive Cancer Centers	Which Financing Options Could Be Used for Therapeutic Innovations?
10.30 - 11.00	Coffee Break		
11.00 - 12.30	PANEL DISCUSSION		
	How Can Treatment Outcomes in the European Union be Improved?		
12.30 - 13.15	Lunch Break		
13.15 - 15.00	PANEL DISCUSSION		
	How Can the European Union Better Position Itself in Cancer Research and Treatment and How Can National Efforts Contribute To This?		
15.00 - 15.30	GET-TOGETHER		

 Handing Out of Conference Documents
08.30 - 10.00

 OPENING
10.00 - 11.30
Ulf Fink

Conference President, former Minister of Health, Berlin

Presentations

Cancer – A Social Challenge
Prof. Richard Schilsky, MD, PhD

Section Chief, Hematology/Oncology; Deputy Director, Comprehensive Cancer Center, University of Chicago, USA

Personalized Cancer Medicine – A Future Challenge
Prof. Dr. Alexander Eggermont

General Director, Institut Gustave Roussy, Villejuif, France; Professor of Surgical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands

The Role of Imaging in Personalized Cancer Medicine
Prof. Hedvig Hricak, PhD

Chair, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA

 PANEL DISCUSSION
11.30 - 13.00
Which Are The Primary Tasks and Responsibilities in European Oncology?

Chair and Introduction of Discussion

Prof. Dr. Ulrik Ringborg

Coordinator, EurocanPlatform; Director, Cancer Center Karolinska, Karolinska University Hospital and Institute, Stockholm, Sweden

Presentations

Translational Cancer Research: Definitions and How to Bridge the Gaps in the Cancer Research Continuum
Prof. Dr. Julio Celis

Scientific Coordinator, EurocanPlatform; Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark

The Role of Industry in Translational Cancer Research
Dr. Gerd Maas

Head, German Translational Research Office, Roche Diagnostics GmbH, Penzberg, Germany

Stimulating Comprehensiveness in Cancer Care
Prof. Dr. Wim H. van Harten

President, Organisation of European Cancer Institutes (OECI); The Netherlands Cancer Institute, Amsterdam, The Netherlands

Design of Cancer Care from the Perspective of a Large Health Insurance Company
Jürgen Malzahn

Head, Department „In-patient care and rehabilitation“, AOK-Bundesverband, Berlin, Germany

Statements

Dr. Tobias Eichhorn

Head, Business Unit Oncology Germany, Pfizer, Berlin, Germany

Dr. Ruxandra Draghia-Akli

Director, Health Research, Directorate General for Research and Innovation, European Commission, Brussels, Belgium

Dr. Gary L. Geipel

Senior Director, Oncology Corporate Affairs, Lilly Deutschland

Discussion

13.00 - 13.45 Lunch Break

SYMPOSIUM

13.45 - 15.15

Central Structural Issues in Europe

Chair and Introduction of Discussion

Dr. Peter Lange, MinDir a.D.

Former Director General, Life Sciences Research for Health, Federal Ministry for Education and Research, Berlin, Germany

Presentations

European Structuring of Cancer Research – the EurocanPlatform Project

Prof. Dr. Ulrik Ringborg

Coordinator, EurocanPlatform; Director, Cancer Center Karolinska, Karolinska University Hospital and Institute, Stockholm, Sweden

Bottle Necks in Translation of Clinical Research Outcomes to Clinical Practice

Prof. Richard Sullivan, MD, PhD

Director, Institute of Cancer Policy, King's College London, United Kingdom

Necessary Structures for Successful Personalized Cancer Medicine

Dr. Michael Warmbold

Vice President, Medical Affairs, Pfizer Oncology Europe

Discussion

15.15 - 15.45 Coffee Break

WORKSHOPS 1 - 3

15.45 - 17.15

WORKSHOP 1

A National Initiative of Translational Cancer Research – the German Consortium of Translational Cancer Research

Chair and Introduction to Subject Issue

Prof. Sir Alexander Markham, MD, PhD

Professor of Medicine, University of Leeds, United Kingdom

Presentations

Structuring Cancer Research by National Networks in the European countries

Prof. Sir Alexander Markham, MD, PhD

Professor of Medicine, University of Leeds, United Kingdom

The German Consortium for Translational Cancer Research

Prof. Dr. Otmar D. Wiestler

Chairman of the Board and Scientific Director, German Cancer Research Center (DKFZ), Heidelberg, Germany

Molecular Diagnostics

Prof. Dr. Peter Lichter

Head of Department, Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany

Immunotherapy

Prof. Dr. Hans-Georg Rammensee

Director, Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard-Karls-University Tübingen, Germany

Radiooncology

Prof. Dr. Michael Baumann

Chair, Department of Radiotherapy, OncoRay – National Center for Radiation Research in Oncology, University Hospital Carl Gustav Carus, Dresden, Germany and Speaker Dresden, German Consortium for Translational Cancer Research (DKTK)

Clinical Communication Platforms

Prof. Dr. Hubert Serve

Director, Department of Medicine II, University Hospital of the Johann Wolfgang Goethe-University, Frankfurt am Main, Germany

Discussion

WORKSHOP 2

What Are the Determining Factors for Successful Translation?

Chair and Introduction to Subject Issue

Prof. Gordon McVie, MD, PhD

Senior Consultant, IEO Istituto Europeo di Oncologia, Milan, Italy

Presentations

The Role of the Healthcare System in Clinical and Late Translational Cancer Research

Prof. Dr. Thomas Tursz

Honorary Director, Institut Gustave-Roussy (IGR), Villejuif, France

How Is Funding Adjusted to Translational Cancer Research?

Prof. Dr. Julio Celis

Scientific Coordinator, EurocanPlatform; Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark

The Role of SMEs in Translational Cancer Research

Prof. Dr. Christoph Driessen

Head, Clinical Trials Unit, Experimental Oncology/Hematology, Kantonsspital St. Gallen, Schweiz

The Role of the Scientific Environment for Successful Translational Research

Dr. Marco Pierotti

Director, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Case Study Microtherapy – From Research to Clinical Application

Prof. Dr. Jens Ricke

Director, Clinic for Radiation and Nuclear Medicine, Otto-von-Guericke-University Magdeburg, University Hospital Magdeburg A.ö.R., Germany

Discussion

WORKSHOP 3

What Differences in Outcomes Exist and How Can the Best Treatments be Standardized Throughout Europe?

Chair and Introduction to Subject Issue

Prof. Dr. Bertram Häussler

Chairman of the Board of Management, IGES Institute GmbH, Berlin, Germany

Presentations

The Eurocourse Programme

Valery Lemmens, PhD

Head, Research Department, Comprehensive Cancer Center South / Eindhoven Cancer Registry, Eindhoven, The Netherlands

Which Infrastructures are Needed for High Quality Outcomes Research?

Prof. Dr. Cornelia Ulrich

Director, NCT National Center for Tumor Diseases; Head, Department for Preventive Oncology, Heidelberg, Germany

Early Detection Programmes in the European Union

Prof. Dr. Alexander Katalinic

Director, Cancer Registry Schleswig-Holstein, Institute for Cancer Epidemiology, University of Lübeck, Germany

Biomarkers – Opportunity for Improving Diagnostics and Therapy

Prof. Dr. Khusru Asadullah

Head, Global Biomarker Function, Bayer HealthCare Pharmaceuticals

Discussion

17.15 - 17.30 Break

PANEL DISCUSSION

17.30 - 18.45

What Needs to Be Improved in Currently Existing Structures for Research and Healthcare?

Chair and Introduction to Subject Issue

Prof. Dr. Ulrik Ringborg

Coordinator, EurocanPlatform; Director, Cancer Center Karolinska, Karolinska University Hospital and Institute, Stockholm, Sweden

Presentation of Results from Workshops 1-3

Prof. Dr. Bertram Häussler

Chairman of the Board of Management, IGES Institute GmbH, Berlin, Germany

Prof. Sir Alexander Markham, MD, PhD

Professor of Medicine, University of Leeds, United Kingdom

Prof. Gordon McVie, MD, PhD

Senior Consultant, IEO Istituto Europeo di Oncologia, Milan, Italy

Statements

Dr. Johannes Bruns

Secretary General, German Cancer Association (Deutsche Krebsgesellschaft e.V.), Berlin, Germany

Prof. Dr. Wolff Schmiegel

Head, Department of Medicine, Ruhr University Bochum, Knappschafts Krankenhaus Bochum, Germany

Discussion

GET-TOGETHER

18.45 - 19.15

Handing Out of Conference Documents

08.30 - 09.00

WORKSHOPS 4-6

09.00 - 10.30

WORKSHOP 4

Which Prevention and Treatment Approaches Promise Success?

Chair and Introduction to Subject Issue

Prof. Anne-Lise Børresen-Dale, PhD, MD

Head, Department of Genetics and The K.G. Jebsen Center for Breast Cancer Research, Institute for Cancer Research, Oslo University Hospital The Norwegian Radium Hospital and Institute for Clinical Medicine, University of Oslo, Norway

Presentations

The Role of Screening for Early Detection

Philippe Autier, MD, PhD

Vice President Population Research, International Prevention Research Institute (iPRI), Lyon, France

Radiation Therapy

Prof. Dr. Daniel Zips

Director, Department Radiation Oncology, University of Tübingen, Germany

Early Diagnosis and Treatment

Prof. Anne-Lise Børresen-Dale, PhD, MD

Head, Department of Genetics and The K.G. Jebsen Center for Breast Cancer Research, Institute for Cancer Research, Oslo University Hospital The Norwegian Radium Hospital and Institute for Clinical Medicine, University of Oslo, Norway

Discussion

WORKSHOP 5

Organizational Concepts for Comprehensive Cancer Centers

Chair and Introduction to Subject Issue

Prof. Dr. Wim H. van Harten

President, Organisation of European Cancer Institutes (OECI); The Netherlands Cancer Institute, Amsterdam, The Netherlands

Presentations

Organizational Quality in Comprehensive Cancer Centers – Recent US Experiences

Prof. Michelle Le Beau, PhD

Director, University of Chicago Comprehensive Cancer Center, Chicago, USA

Scientific Management –

Organization of Translational Cancer Research

Prof. Dr. Anton Berns

The Netherlands Cancer Institute, Amsterdam, The Netherlands

The Role of Accreditation and Designation Upgrading

Dr. Mahasti Saghatchian

Chair Accreditation-Designation OECI; Medical Oncologist, Breast Cancer Unit and Executive in charge of European and International Affairs, Institute Gustave Roussy (IGR), Villejuif, France

Discussion

WORKSHOP 6

Which Financing Options Could Be Used for Therapeutic Innovations?

Chair and Introduction to Subject Issue

Dr. Siegfried Bialojan

Executive Director, Head European Life Science Center,
Ernst & Young AG, Mannheim, Germany

Presentations

Example of a Budding Biotech Firm – Venture Capitalism, What Are the Chances and Challenges?

Dr. Andreas Jordan

Founder and Board, Research and Development, MagForce AG,
Berlin, Germany

Approaches to Balancing Effects of Treatments to Costs

Dr. Elisabeth George

Technology Appraisals, Centre for Public Health Excellence, NICE,
London, United Kingdom

Principles of Cost-Effectiveness in Oncology

Mike Spencer

Senior Director, HEMAR Oncology and Immunology,
EMEA Region at Janssen-Cilag Ltd., High Wycombe, United Kingdom

Discussion

10.30 - 11.00 Coffee Break

PANEL DISCUSSION

11.00 - 12.30

How Can Treatment Outcomes in the European Union Be Improved?

Chair and Introduction to Subject Issue:

Prof. Dr. Reinhard Busse, MPH, FFPH

Director, European Observatory on Health Systems and Policies; Professor, Faculty of Economics and Management, Technische Universität Berlin, Germany

Presentation of Results from Workshops 4-6

Dr. Siegfried Bialojan

Executive Director, Head European Life Science Center,
Ernst & Young AG, Mannheim, Germany

Prof. Anne-Lise Børresen-Dale, PhD, MD

Head, Department of Genetics and The K.G. Jebsen Center for Breast Cancer Research, Institute for Cancer Research, Oslo University Hospital The Norwegian Radium Hospital and Institute for Clinical Medicine, University of Oslo, Norway

Prof. Dr. Wim H. van Harten

President, Organisation of European Cancer Institutes (OEI);
The Netherlands Cancer Institute, Amsterdam, The Netherlands

Statements

Mojca Gobec, MD

Coordinator, European Partnership for Measures to Control Cancer and Director General for Public Health, Ministry of Health, Ljubljana, Slovenia

Prof. Dr. Josep M. Borràs

Scientific Coordinator, Spanish Cancer Strategy;
Professor, University of Barcelona, Spain

Dr. Johannes Bruns

Secretary General, German Cancer Association
(Deutsche Krebsgesellschaft e. V.), Berlin, Germany

Richard Bergström

Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA) Brussels Office, Belgium

Discussion

12.30 - 13.15 Lunch Break

PANEL DISCUSSION

13.15 - 15.00

How Can the European Union Better Position Itself in Cancer Research and Treatment and How Can National Efforts Contribute To This?

Chair and Introduction to Subject Issue

Prof. Dr. Ulrik Ringborg

Coordinator, EurocanPlatform; Director, Cancer Center Karolinska, Karolinska University Hospital and Institute, Stockholm, Sweden

Discussants

Dr. Angela Lindner

Head, Department Health Research,
Federal Ministry of Education and Research, Berlin, Germany

Prof. Dr. Julio Celis

Scientific Coordinator, EurocanPlatform; Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark

Prof. Dr. Wim H. van Harten

President, Organisation of European Cancer Institutes (OEI);
The Netherlands Cancer Institute, Amsterdam, The Netherlands

Richard Bergström

Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA) Brussels Office, Belgium

Dr. Christian Lenz

Outcome Research Director, Pfizer Oncology Europe

GET-TOGETHER

15.00 - 15.30



EUROPEAN FORUM ON ONCOLOGY 2012

Advances in Cancer Therapy

3rd and 4th May 2012
Hotel Concorde BERLIN

Location

Hotel Concorde Berlin

Augsburger Str. 41
10789 Berlin

PHONE +49 30 800 999 0
FAX +49 30 800 999 99

Conference Office

EUROPEAN FORUM ON ONCOLOGY 2012

Französische Str. 23
10117 Berlin

PHONE +49 30 70011 7600
FAX +49 30 70011 7604

kongress@forum-onkologie.eu
www.forum-onkologie.eu

Coordination

Gesundheitsstadt Berlin GmbH

Dr. Franz Dormann
Managing Director

www.gesundheitsstadt-berlin.de

Organizer

WISO S. E. Consulting GmbH

Dr. Ingrid Völker
Chief Executive Officer

www.wiso-gruppe.de

Date of Publication: 24 February 2012

Latest updates and registration on:

www.forum-onkologie.eu

REGISTRATION

EUROPEAN FORUM ON ONCOLOGY 2012

- I register with binding effect as an employee of a hospital at the hospital fee of 490.00 EUR (583.10 EUR incl. 19% VAT).
- I register with binding effect as an employee of a scientific research institute at the special price of 300.00 EUR (357.00 EUR incl. 19% VAT).
- I register with binding effect at the standard rate of 860.00 EUR (1,023.40 EUR incl. 19% VAT).

Ms. Mr.

Title

First Name

Family Name

Function

Name of Hospital

Name of the Research Institute

Institution

- | | | |
|--|---|---|
| <input type="checkbox"/> Hospital | <input type="checkbox"/> Research / Academy | <input type="checkbox"/> Private Practice |
| <input type="checkbox"/> Industry / Business | <input type="checkbox"/> NGO | <input type="checkbox"/> Insurance |
| <input type="checkbox"/> Public Administration | <input type="checkbox"/> Journalism | <input type="checkbox"/> Other |

Billing Address

Institution / Company

Department

Street, Number

Postal Code, City

Telephone

Telefax

E-Mail

Date, Signature

Payment / Hotel

Following registration, you will be sent an invoice. A limited number of rooms is available at the Hotel Concorde Berlin for attendees, key words: "Forum Oncology".

Accreditation as Continuing Medical Training

The **EUROPEAN FORUM ON ONCOLOGY 2012** has been certified as continuing medical training (12 points).

Cancellation

This registration is binding but can be transferred to comparable parties at any time. Cancellations must be submitted in writing to the Conference Office. No refunds will be provided for cancellations received after 30 March 2012. This also applies for any registration submitted after 30 March 2012.

Kindly register by fax +49 30 70011 7604 or window envelope.

Online registration on www.forum-onkologie.eu

www.forum-onkologie.eu

EUROPEAN FORUM ON
ONCOLOGY 2012
Französische Straße 23
10117 Berlin

PARTNER



Oncology



and SIEMENS | Bayer HealthCare Pharmaceuticals

MEDIA PARTNERS

ecancermedicalsecience

EUROPEAN HOSPITAL
THE EUROPEAN HUB FOR HEALTH CARE BUSINESS IN EUROPE

DER TAGESSPIEGEL
1848

Springer
ÄRZTE ZEITUNG

kma
Der Gesundheitsauftraggeber